Yan Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yan Lin has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Donghua Tian
School of Social Development and Public Policy, China Institute of Health, Beijing Normal University, Beijing, 100875, China
1 shared publication- Guodong Li
School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China
1 shared publication - Ranran Shi
Respiratory Medicine Department , Luohe Central Hospital , Luohe 462000 , China , lhzxyy.com.cn
1 shared publication - Weijun Zhang
Department of Cerebral Function The Second Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou China
1 shared publication - Wenwen Liu
School of Life Sciences Zhengzhou University Zhengzhou 450001 China zzu.edu.cn
1 shared publication - Xiuman Zhou
School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China
1 shared publication
Latest Publications
- Open Access
- 5 January 2021
- Published by Wiley in Journal of Immunology Research
- Vol. 2021, 1-13
Identification of CTL Epitopes on Efflux Pumps of the ATP-Binding Cassette and the Major Facilitator Superfamily of Mycobacterium tuberculosis
Tuberculosis is the worlds most deadly infectious disease, with 10 million people falling ill and 1.5 million people dying from the disease every year. With the increasing number of drug-resistant Mycobacterium tuberculosis (MTB) strains and prevalence of coinfection of MTB with human immunodeficiency virus, many challenges remain in the prevention and treatment of tuberculosis. Therefore, the development of safe and effective tuberculosis vaccines is an urgent issue. In this study, we identified cytotoxic T lymphocyte epitopes on drug resistance-associated membrane protein efflux pumps of MTB, the ATP-binding cassette and the major facilitator superfamilies. First, three online software were used to predict HLA-A2-restricted epitopes. Then, the candidate epitopes were confirmed with the T2A2 cell binding affinity and peptide/MHC (pMHC) complex stability assays and in vitro immune activity experiments. Two drug-resistant T lymphocyte epitopes, designated Rv1218c-p24 and Rv2477c-p182, were selected, and their immunogenic activities studied in vivo in genetically engineered mice. The immune activities of these two epitopes were improved with the help of complete Freunds adjuvant (CFA). The epitopes identified here provide a foundation for the diagnosis and treatment of patients infected with drug resistant and the future development of a multiepitope vaccine.
- 5 January 2021
- Published by Wiley in Journal of Immunology Research
- Vol. 2021, 1-13
Open AccessIdentification of CTL Epitopes on Efflux Pumps of the ATP-Binding Cassette and the Major Facilitator Superfamily of Mycobacterium tuberculosis
Tuberculosis is the worlds most deadly infectious disease, with 10 million people falling ill and 1.5 million people dying from the disease every year. With the increasing number of drug-resistant Mycobacterium tuberculosis (MTB) strains and prevalence of coinfection of MTB with human immunodeficiency virus, many challenges remain in the prevention and treatment of tuberculosis. Therefore, the development of safe and effective tuberculosis vaccines is an urgent issue. In this study, we identified cytotoxic T lymphocyte epitopes on drug resistance-associated membrane protein efflux pumps of MTB, the ATP-binding cassette and the major facilitator superfamilies. First, three online software were used to predict HLA-A2-restricted epitopes. Then, the candidate epitopes were confirmed with the T2A2 cell binding affinity and peptide/MHC (pMHC) complex stability assays and in vitro immune activity experiments. Two drug-resistant T lymphocyte epitopes, designated Rv1218c-p24 and Rv2477c-p182, were selected, and their immunogenic activities studied in vivo in genetically engineered mice. The immune activities of these two epitopes were improved with the help of complete Freunds adjuvant (CFA). The epitopes identified here provide a foundation for the diagnosis and treatment of patients infected with drug resistant and the future development of a multiepitope vaccine.
- 1 February 2013
- Published by Elsevier in Journal of Virological Methods
- Vol. 187 (2) , 304-313
Identification of three H-2Kd restricted CTL epitopes of NS4A and NS4B protein from Yellow fever 17D vaccine
- 1 February 2013
- Published by Elsevier in Journal of Virological Methods
- Vol. 187 (2) , 304-313
Identification of three H-2Kd restricted CTL epitopes of NS4A and NS4B protein from Yellow fever 17D vaccine